Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

batifiban

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
The combined use of batifiban, a synthetic platelet GPII b/ IIIa receptor antagonist, and antithrombin agents is an attractive… Expand
  • figure 1
  • table 1
  • table 3
2013
2013
SummaryThe combined use of batifiban, a synthetic platelet GPII b/ IIIa receptor antagonist, and antithrombin agents is an… Expand
2013
2013
  • H. Ji
  • 2013
  • Corpus ID: 75344868
Objective To observe the clinical effect and safety of batifiban in non-ST segment elevation acute coronary syndrome(ACS)patients… Expand
2013
2013
Objective To explore the effect of batifiban on platelet aggregation during and after percutaneous coronary intervention(PCI) in… Expand
2009
2009
SummaryBatifiban, a synthetic cyclic peptide, is a potent platelet glycoprotein GPIIb/IIIa antagonist which may be useful in the… Expand
2009
2009
Batifiban, a synthetic cyclic peptide, is a potent platelet glycoprotein GPIIb/IIIa antagonist which may be useful in the… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 4
2008
2008
Batifiban, a synthetic cyclic peptide, is a potent platelet glycoprotein GPIIb/IIIa antagonist that may be useful in treating and… Expand
  • figure 2
  • figure 3
  • table 1
  • table 2
  • table 3